<DOC>
	<DOCNO>NCT00237016</DOCNO>
	<brief_summary>Abstract Background Tick-Borne Relapsing Fever ( TBRF ) acute febrile illness . In Israel , TBRF cause Borrelia persica transmit Ornithodoros tholozani tick . We examine safety efficacy post exposure treatment policy prevent TBRF . Methods In double blind , placebo control trial 93 healthy volunteer suspect tick exposure ( 51 bite sign 42 contact ) randomly assign receive either Doxycycline ( 200 mg first day 100mg/d 4 day ) placebo , approximately 2 day contact . Blood smear examine Borrelia inclusion fever rise . Serology Lyme disease cross- reactivity PCR Borrelia GlpQ gene also perform . Cases TBRF define subject fever positive blood smear .</brief_summary>
	<brief_title>Post Exposure Treatment With Doxycycline Prevention Relapsing Fever</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Relapsing Fever</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>suspect exposure tickborne relapse fever return field exercise tickborne relapsing fever infect area tick bite stay field close proximity subject tick bite sign know sensitivity tetracycline doxycycline febrile illness recruitment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
</DOC>